Analyzing the Price-to-Earnings Ratio of Calidi Biotherapeutics Inc (CLDI)

The 36-month beta value for CLDI is also noteworthy at 0.60. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for CLDI is 31.30M, and at present, short sellers hold a 0.94% of that float. The average trading volume of CLDI on June 10, 2024 was 1.25M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

CLDI) stock’s latest price update

The stock price of Calidi Biotherapeutics Inc (AMEX: CLDI) has jumped by 3.63 compared to previous close of 0.19. Despite this, the company has seen a fall of -9.09% in its stock price over the last five trading days. reported 2024-06-10 that SAN DIEGO–(BUSINESS WIRE)—- $CLDI #immunotherapy–Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors.

CLDI’s Market Performance

CLDI’s stock has fallen by -9.09% in the past week, with a monthly drop of -13.79% and a quarterly drop of -67.37%. The volatility ratio for the week is 15.06% while the volatility levels for the last 30 days are 18.10% for Calidi Biotherapeutics Inc The simple moving average for the last 20 days is -12.84% for CLDI’s stock, with a simple moving average of -89.20% for the last 200 days.

Analysts’ Opinion of CLDI

Many brokerage firms have already submitted their reports for CLDI stocks, with H.C. Wainwright repeating the rating for CLDI by listing it as a “Buy.” The predicted price for CLDI in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on November 22, 2023 of the previous year 2023.

Robert W. Baird, on the other hand, stated in their research note that they expect to see CLDI reach a price target of $9. The rating they have provided for CLDI stocks is “Outperform” according to the report published on October 09th, 2023.

CLDI Trading at -30.85% from the 50-Day Moving Average

After a stumble in the market that brought CLDI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.55% of loss for the given period.

Volatility was left at 18.10%, however, over the last 30 days, the volatility rate increased by 15.06%, as shares sank -11.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.08% lower at present.

During the last 5 trading sessions, CLDI fell by -5.18%, which changed the moving average for the period of 200-days by -97.36% in comparison to the 20-day moving average, which settled at $0.2281. In addition, Calidi Biotherapeutics Inc saw -86.75% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CLDI

Equity return is now at value -212.68, with -85.99 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 0.13.


In summary, Calidi Biotherapeutics Inc (CLDI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts